Development, structure, and mechanism of synthetic antibodies that target claudin and Clostridium perfringens enterotoxin complexes

Received for publication, April 23, 2022, and in revised form, August 1, 2022. Published, Papers in Press, August 9, 2022, https://doi.org/10.1016/j.jbc.2022.102357

Benjamin J. Orlando, Pawel K. Dominik, Sourav Roy, Chinemerem P. Ogbu, Satchal K. Erramilli, Anthony A. Kossiakoff, and Alex J. Vecchio

From the 1Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan, USA; 2Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois, USA; 3Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, Nebraska, USA

Edited by Karen Fleming

Strains of Clostridium perfringens produce a two-domain enterotoxin (CpE) that afflicts humans and domesticated animals, causing prevalent gastrointestinal illnesses. CpE’s C-terminal domain (cCpE) binds cell surface receptors, followed by a restructuring of its N-terminal domain to form a membrane-penetrating β-barrel pore, which is toxic to epithelial cells of the gut. The claudin family of membrane proteins are known receptors for CpE and also control the architecture and function of cell-cell contacts (tight junctions) that create barriers to intercellular molecular transport. CpE binding and assembly disables claudin barrier function and induces cytotoxicity via β-pore formation, disrupting gut homeostasis; however, a structural basis of this process and strategies to inhibit the claudin–CpE interactions that trigger it are both lacking. Here, we used a synthetic antigen-binding fragment (sFab) library to discover two sFabs that bind claudin-4 and cCpE complexes. We established these sFabs’ mode of molecular recognition and binding properties and determined structures of each sFab bound to claudin-4–cCpE complexes using cryo-EM. The structures reveal that the sFabs bind a shared epitope, but conform distinctly, which explains their unique binding equilibria. Mutagenesis of antigen/sFab interfaces observed therein result in binding changes, validating the structures, and uncovering the sFab’s targeting mechanism. From these insights, we generated a model for CpE’s claudin-bound β-pore that predicted sFabs would not prevent cytotoxicity, which we then verified in vivo. Taken together, this work demonstrates the development and mechanism of claudin/cCpE-binding sFabs that provide a framework and strategy for obstructing claudin/CpE assembly to treat CpE-linked gastrointestinal diseases.

Tight junctions are molecular gatekeepers that regulate transport of small molecules through the paracellular spaces between adjoining cells in endothelia and epithelia. To accomplish this function, tight junctions possess integral membrane proteins that self-assemble to simultaneously span both intracellular and paracellular spaces (1, 2). Of the numerous membrane proteins at tight junctions, the 27-member family of claudins comprise the major structural and functional backbone of tight junctions, making them attractive targets to modulate tight junction barriers therapeutically (3). Evolution has successfully accomplished this feat. Type F strains of the pathogenic Gram-positive bacterium Clostridium perfringens produce an enterotoxin (CpE) that binds claudins to dissociate tight junctions during cytotoxicity in the gut (4–6). In domesticated animals, CpE causes necrotic enteritis, colitis, and diarrhea (7, 8). In humans, CpE causes enterotoxemia, which is the third most prevalent foodborne illness in the United States causing an estimated ~$400 million annual economic burden and is the source of a further 4+ million food poisoning cases worldwide—some resulting in death (8–12). Unlike other human diseases caused by C. perfringens toxins, CpE-associated ailments are not directly preventable nor treatable, and no vaccine exists against this food poisoning type (13). Because spore-formed C. perfringens is heat-resistant, cooking does little to reduce its pathogenicity, as digested spores can produce CpE (14). Therefore, sub-molecular details into CpEs mechanisms of claudin binding and dissociating tight junction barriers are essential to elucidate CpE cytotoxicity and to develop therapeutic strategies for CpE-based diseases.

The C-terminal domain of CpE (cCpE) selectively targets claudins in the gut by recognizing a motif unique to these receptors, then binds them with low nanomolar affinities (15, 16). This claudin-bound CpE, that is, “small complex”, then oligomerizes and its N-terminal domain structurally rearranges to form a membrane-penetrating and cytotoxic β-barrel pore (17, 18). The process of β-pore formation disables claudin–claudin interactions vital to tight junction assembly and ultimately dissociates tight junctions causing paracellular leakage prior to CpE-induced cell death. Crystal structures of cCpE bound to receptor claudins have shed light on their interprotein interactions and have helped to inform structure-guided design of modified cCpEs used to detect or destroy...
Cryo-EM structures of claudin–enterotoxin complexes by Fabs

cancer cells or to modulate the blood-brain barrier for drug delivery (16, 19–26). Yet, a complete structural and mechanistic understanding of CpE dissociation of tight junctions and the process of cytotoxic β-pore formation remains elusive.

We intended to elucidate how CpE binds claudins and dissociates tight junctions by determining X-ray crystal structures of enterotoxins CpE or cCpE in complex with claudins but found crystallization to be a bottleneck. For most claudins, crystals did not form at all, while for those that formed crystals, it required screening and optimizing hundreds over ~1 year to determine structures resolved to 3 to 4 Å (16, 24). Using a phage display, library-encoding synthetic antigen-binding fragments (sFabs), we sought to discover molecules that target and bind complexes between enterotoxins and human claudin-4 (claudin-4). Our goal was to use sFabs to chaperone crystallization, improve initial diffraction, and increase structural throughput of this and other claudin–enterotoxin complexes (27, 28). Through this approach, we surmised additional sFabs could discover that obstruct complex formation altogether and be useful in therapeutic development. During this process, three sFabs were discovered, which we termed CpE Obstructing Proteins (COPs). Preliminary characterization of COPs revealed that COP-2 and COP-3 had properties amenable for structure determination of the claudin-4–cCpE complex. Ultimately, however, we determined a structure of this complex using a traditional crystallography workflow (16). But because sFabs have recently been shown effective for determining structures of small membrane proteins and complexes by cryo-EM, we used COP-2, COP-3, and cryo-EM to progress a novel workflow for higher throughput elucidation of claudin/enterotoxin structures (29–31).

Here, we qualitatively and quantitatively characterize COP-2 and COP-3 binding to claudin-4, CpE, and cCpE individually, and to claudin-4–enterotoxin complexes using biochemical and biophysical techniques. We also use cryo-EM at 200 kV to determine 4 to 7 Å structures of each 50 kDa COP bound to ~35 kDa claudin-4–cCpE complexes in ~1 month and employ these structures to create models of the cytotoxic CpE β-pore. Our findings reveal the structural basis and COP-specific mechanisms of COP targeting of claudin-4–cCpE complexes. This research independently validates claudin-4/cCpE structures determined by X-ray crystallography and provides a structural framework for preventing CpE-mediated cytotoxicity by obstructing toxin/receptor binding. Moreover, it advances development of technologies and establishes a general approach for determining structures of other claudin–enterotoxin complexes at moderate resolutions using accessible cryo-EM instrumentation that can readily be expanded to higher resolutions with 300 kV microscopes. Further, it demonstrates the antigenicity of CpE and cCpE enterotoxins and their claudin-bound complexes, which through intensified sFab development could generate novel sFabs useful for modulating tight junction barriers or as therapeutics for preventing or treating CpE-based illnesses in humans and domesticated animals.

Results

Development of COPs

Claudin-4 solubilized in n-dodecyl-β-D-maltopyranoside (DDM) and bound to cCpE was used as input for phage display selection using a large and diverse library of sFabs based on a humanized Fab scaffold. The sFab library has varied sequences that are biased for serine and tyrosine in the complementarity-determining regions (CDRs) of their light (L) and heavy (H) chains within variable domains (32, 33). After several rounds of selection to increase stringency, two sFabs, termed COP-2 and COP-3, were further developed and validated by ELISA to bind to claudin-4/cCpE. Both COPs were sequenced and isolated to characterize their binding further. Sequence alignments of COP-2 and COP-3 reveal that COP-2 and COP-3 share 98.2 and 93.3% sequence identity in their L and H chains, respectively; and that COP sequences diverge the greatest in CDR-L3, CDR-H1, and CDR-H3 (Supporting Information (SI) Fig. S1). These residue divergences may direct COP-specific recognition of claudin-4–cCpE complexes.

Biochemical characterization of COPs

To obtain more detailed insights into COP recognition, we determined which molecule COPs bind and if they use unique or common epitopes. After expressing and purifying claudin-4, cCpE, CpE, and COPs, increases in molecular masses as assessed by decreases in peak retention times with size-exclusion chromatography (SEC) was used to qualitatively characterize COP-2 and COP-3 binding modes. After incubating COP-2 and COP-3 with claudin-4 and cCpE alone, we found that COPs did not bind claudin-4 but did form larger complexes with cCpE (Fig. 1, A and B). Incubating claudin-4, cCpE, and COPs together showed that cCpE binds claudin-4 and that both COPs bound claudin-4–cCpE complexes (Fig. 1C). No mass increases were observed for COPs incubated with CpE (Fig. 1D). Lastly, incubating claudin-4, CpE, and COPs together showed that while CpE binds claudin-4 and forms a "small complex", the COPs did not bind "small complexes" (Fig. 1E). To verify complex formation, peaks from SEC were pooled and subjected to SDS-PAGE, which showed the presence of individual proteins from associated complexes (Fig. 1F). To determine if COPs share a binding epitope, we incubated COP-2 and COP-3 together with cCpE. If COPs bound distinct epitopes, a molecular mass shift greater than the individual cCpE–COP complex would result. SEC revealed no additive mass shift with both COPs present (Fig. 1B). These biochemical results suggest the specific molecular recognition of COPs and that COPs share binding epitopes.

Biophysical characterization of COPs

After qualitatively establishing COP binding, we quantitated the affinities and kinetics of COP interactions with claudin-4 and enterotoxins. We determined the second-order association rate constant (k_{on}), first-order dissociation rate constant (k_{off}), and equilibrium dissociation constant (K_{D}) of these
interactions using bio-layer interferometry (BLI) (Table 1; SI Fig. S2). BLI measurements were made using preformed claudin-4–enterotoxin complexes or cCpE alone in DDM, replicating the conditions of the phage display selections. For COP-2 and COP-3 binding to claudin-4–cCpE complexes, we measured KDs of 52.3 and 98.4 nM, respectively. Comparing the binding rates revealed that COP-3 had 1.9- and 3.5-fold faster kon and koff rates than COP-2. The KDs of COP-2 and COP-3 to cCpE were 67.6 and 137.6 nM, respectively. Like COP-3 binding to claudin-4–cCpE complexes, the kon and koff rates were 1.4- and 2.1-fold faster than COP-2. Finally, we measured KDs of 7.8 and 9.1 μM for COP-2 and COP-3 binding to claudin-4/CpE “small complexes”, respectively. The KD values represent 149.1- and 92.0-fold decreases in COP-2 and COP-3 affinity for CpE compared to cCpE. Kinetic differences in kon and koff of COP binding to cCpE are visible in the BLI sensorgrams (SI Fig. S2). These results agree with biochemical assessment and reveal biophysical parameters unique to each COP that may influence recognition and binding to claudin-4–cCpE complexes.

Cryo-EM structures of claudin–enterotoxin complexes by Fabs

Having confirmed that COP-2 binds claudin-4–cCpE complexes using SEC (Fig. 2A) and BLI (Fig. 2B), we next delineated the structural basis and molecular mechanism of COP-2 targeting by determining its structure by cryo-EM. Cryo-EM screening of claudin-4–cCpE–COP-2 complexes that were SEC purified, pooled, and concentrated to 8.0 mg/ml in various detergents showed that those solubilized in 2,2-didecylpropane-1,3-bis-β-D-maltopyranoside (LMNG) were amenable to structure determination. This was confirmed by 2D classifications and ab initio 3D reconstructions, which revealed a stacked and linear arrangement of the three

Table 1

| COP      | Complex/Protein | kon (1/Ms) | koff (1/s) | KD (nM) |
|----------|----------------|------------|------------|---------|
| COP-2    | claudin-4/cCpE | 1.5x10^4 ± 0.1x10^4 | 7.8x10^4 ± 0.6x10^4 | 523 ± 3.0 |
|          | cCpE           | 7.2x10^3 ± 0.6x10^3 | 4.8x10^4 ± 0.9x10^4 | 676 ± 11.7 |
| COP-3    | claudin-4/cCpE | 1.5x10^4 ± 0.6x10^2 | 1.2x10^3 ± 0.6x10^3 | 7800 ± 750 |
|          | cCpE           | 2.9x10^3 ± 0.7x10^4 | 2.7x10^3 ± 0.5x10^3 | 984 ± 11.0 |
|          | claudin-4/CpE  | 1.0x10^4 ± 0.1x10^4 | 1.0x10^3 ± 0.1x10^3 | 137.6 ± 6.2 |
|          | claudin-4/CpE  | 1.2x10^4 ± 0.2x10^3 | 10.8x10^2 ± 0.7x10^2 | 9050 ± 1300 |
proteins, a canonical two-lobed sFab, and flexibility in COP-2’s constant domain (SI Fig. S3). Due to this flexibility, we used a data processing strategy that masked claudin-4, cCpE, and the variable domains of COP-2 to resolve and focus understanding on the interactions directing COP-2 recognition. Using this strategy, a cryo-EM map that was resolved to 6.9 Å was generated (SI Table S1). The map resolution was sufficient to reveal the claudin-4–cCpE–COP-2 complex, secondary structural elements including claudin-4’s four transmembrane helices (TM), and some bulky side chains (SI Fig. S4A). This cryo-EM map was used to build, refine, and determine a structure for the claudin-4–cCpE–COP-2 complex. SI Table S1 shows data processing, refinement, and model-to-map fit statistics, with further details given in Experimental procedures.

Overall, however, the claudin-4/cCpE portion of this complex from cryo-EM superimposed well onto the crystal structure (SI Fig. S5A). We measured RMSDs in Cα positions of 2.0 and 1.4 Å between the cores of claudin-4 and cCpE and 1.7 Å in overall secondary structures between the cryo-EM and crystal structures of the claudin-4–cCpE complex, indicating no

Figure 2. Structure and function of COP-2 binding to claudin-4–cCpE complexes. A, SEC purification of human claudin-4 (hCLDN-4)–cCpE–COP-2 complexes in LMNG. SEC elution times of MW standards are shown by X axis. B, binding of COP-2 to claudin-4/cCpE using BLI. C, cryo-EM structure of COP-2 (blue) bound to cCpE (copper) and hCLDN-4 (teal). The cryo-EM map (gray mesh) is contoured to 4.0 σ. cCpE, CpE obstructing protein; SEC, size-exclusion chromatography; BLI, bio-layer interferometry.
major conformational changes occur upon COP-2 binding. Generally, the claudin-4 extracellular segments (ECSs) are in similar conformations and thus may interact with cCpE similarly in the cryo-EM and crystal structures (SI Fig. S5A). Density corresponding to a loop within ECS2 that contains the NPLVA motif shows that the motif accesses a groove on the surface of cCpE. This interaction is known to impart high-affinity cCpE binding to claudins, and COP-2 appears to not significantly alter its structure (16).

The cryo-EM structure of the claudin-4–cCpE–COP-2 complex reveals the basis of COP-2 binding. The canonical binding of cCpE to claudin-4 exposes cCpE’s top half to COP-2 binding by providing an antigenic surface (Fig. 2C). COP-2 binding to cCpE alters the conformations of cCpE’s N-terminus, \( \beta \)-strands \( \beta^5 \) and \( \beta^6 \), and the loop connecting them, when compared to the crystal structure (SI Fig. S5A). COP-2’s L chain sits atop a depression on the exterior of cCpE formed between the N-terminus and strands \( \beta^5 \) and \( \beta^6 \) (Fig. 2C). Chain L’s CDR-L1, CDR-L2, and CDR-L3 conform to the surface of cCpE, and potential side chains involved in these interactions can be visualized although not placed confidently (Fig. 4, A and B). COP-2’s chain H accesses the same surface depression as chain L but also flanks the opposite side of strands \( \beta^5 \) and \( \beta^6 \). – Claudin-4 H3 shares an epitope with chain L while CDR-H1 and CDR-H2 reside on the other (Fig. 2C and Fig. 4C). COP-H3 splays outward to deeply penetrate its surface groove, conforming to the cCpE surface (Fig. 4D). Based on the interactions projected by the structure, we hypothesized that residues comprising Lys197 to Leu202 and Asn267 to Gln276 in cCpE could influence COP-2 binding.

After verifying that COP-3 binds claudin-4–cCpE complexes using SEC (Fig. 3A) and BLI (Fig. 3B), we next determined a structure for COP-3 in complex with claudin-4/cCpE by cryo-EM to contrast its molecular mechanism of targeting with COP-2. Claudin-4–cCpE–COP-3 complexes in various membrane mimetics were SEC purified, pooled, and concentrated to 6.0 mg/ml for cryo-EM. Those complexes solubilized with no mask, which produced a map (whole) that was resolved to 5.0 Å. The whole map resolved the claudin-4–cCpE–COP-3 complex, including secondary structural elements like claudin-4’s TM, \( \alpha \)-helices and \( \beta \)-strands in cCpE, and the conformations of COP-3 CDRs (SI Fig. S4B). Initial model building and refinement employed both maps, but the final model was refined against the whole map, resulting in the cryo-EM structure for the claudin-4–cCpE–COP-3 complex. SI Table S1 shows data processing, refinement, and model-to-map fit statistics, with further details given in Experimental procedures.

The cryo-EM structure of the claudin-4–cCpE–COP-3 complex reveals COP-3’s mode of binding. Compared to the claudin-4/cCpE crystal structure, the equivalent portion from the COP-3 cryo-EM structure superimposes well and indicates that COP-3 does not induce large conformational changes or affect normal claudin-4–cCpE interactions (SI Fig. S5B). We measured RMSDs in \( \alpha \)-positions of 2.2 and 1.2 Å between the cores of claudin-4 and cCpE and 2.1 Å between overall secondary structures in the claudin-4–cCpE complex when comparing cryo-EM and X-ray structures. Like COP-2, COP-3 accesses cCpE’s surface opposite to where claudin-4 binds due to their canonical interactions (Fig. 3C). COP-3 binding to cCpE alters cCpE’s N-terminus, \( \beta^5 \) and \( \beta^6 \), and the loop connecting them, when compared to the crystal structure (SI Fig. S5B). The L chain of COP-3 binds between cCpE’s N-terminus and \( \beta^5 \) and \( \beta^6 \) using CDR-L1 and CDR-L3 (Fig. 4E). The CDR-L3 loop conforms to the surface of this region, potentially using aromatic side chains to drive shape complementarity (Fig. 4F). COP-3’s H chain flanks both sides of \( \beta^5 \) and \( \beta^6 \) of cCpE with CDR-H3 sharing an epitope with chain L while CDR-H1 and CDR-H2 occupy the other side (Fig. 3C and Fig. 4G). COP-3’s CDR-H3 conforms to and deeply accesses a surface groove between this region and the N-terminus (Fig. 4H). Based on the interactions approximated by the structure, we hypothesized that residues comprising Glu198 to Leu202 and Asn269 to Gln276 in cCpE may guide COP-3 binding.

**Comparison of COP structures**

Because structure resolution was limiting, we used computational analyses to estimate the COP-specific residues used for cCpE recognition. For this, we input the structures into PDBePISA to determine the properties of the protein interfaces and then compared areas determined by PDBePISA to preside over cCpE/COP binding with COP primary sequences (SI Fig. S1) (34). For COP-2, we found that CDR-L3 residues Tyr117 to Ala120, CDR-H1 residue Ser56, and CDR-H3 residues Tyr125 to Ser137 were unique. For COP-3, we found that CDR-L3 residues His117 to Tyr121, CDR-H1 and CDR-H2 occupy the other side (Fig. 3C and Fig. 4G). COP-3’s CDR-H3 forms to and deeply accesses a surface groove between this region and the N-terminus (Fig. 4H). Based on the interactions approximated by the structure, we hypothesized that residues comprising Glu198 to Leu202 and Asn269 to Gln276 in cCpE may guide COP-3 binding.
differences between complexes but the claudin-4 TMs are oriented differently in membrane mimetics; and 3) the COPs have similar secondary structural elements, but their tertiary structures and CDRs vary in conformations (Fig. 5A). Focusing on regions with the largest observable differences, we found that the L and H chains of each COP conform to cCpE uniquely. For COP-2 chain L, CDR-L1 and CDR-L3 reside within the surface groove formed between the N-terminus and β5-β6 of cCpE while CDR-L2 lies external (Fig. 5B). For COP-3 chain L, the surface groove is depressed due to less N-terminal length, so while CDR-L1 and CDR-L3 reside in the same groove, CDR-L1 appears to interact less with cCpE. The conformation of CDR-H3 may force this CDR-L1 change in COP-3. With PDBePISA, we calculated interface surface areas between the L chain of COPs and cCpE and found that COP-2’s area was ~36% larger. In both COP’s chain H, the CDR-H1 and CDR-H2 bind on one side of cCpE’s β5-β6 element while CDR-H3 flanks the other (Fig. 5C). While CDR-H1 and CDR-H2 have similar conformations and sequence alignments show that residue conservation is high, CDR-H3 conformations appear to vary and residue conservation is low (SIFig. S1). Generally, the three CDR conformations overlay well between both COPs, which is reflected by cCpE/H chain interface surface area differences of only ~5%. For both COPs, ~80% of the total cCpE/COP interface area residues in chain H. Overall, COP-2 appears to use chain L to a higher degree than COP-3.

Figure 3. Structure and function of COP-3 binding to claudin-4–cCpE complexes. A, SEC purification of hCLDN-4–cCpE–COP-3 complexes in amphipol. SEC MW standard elution times are shown by X axis. B, binding of COP-3 to claudin-4/cCpE using BLI. C, cryo-EM structure of COP-3 (red) bound to cCpE (copper) and hCLDN-4 (teal). The cryo-EM map (gray mesh) is contoured to 5.0 σ. cCpE, CpE’s C-terminal domain; COP, CpE obstructing protein; SEC, size-exclusion chromatography; BLI, bio-layer interferometry.
Figure 4. COP recognition of cCpE epitopes. Potential interactions between COP-2 (blue) and cCpE (copper) for the following: (A and B) chain L (light blue) and (C and D) chain H (dark blue). COP-2 and cCpE are both represented as cartoons (A and C) or COP-2 as a cartoon and cCpE as a surface (B and D). Potential interactions between COP-3 (red) and cCpE (copper) for the following: (E and F) chain L (red) and (G and H) chain H (maroon). COP-3 and cCpE are both represented as cartoons (E and G) or COP-3 as a cartoon and cCpE as a surface (F and H). cCpE, CpE’s C-terminal domain; COP, CpE obstructing protein.
while both COPs use chain H similarly and dominantly to bind cCpE. Moreover, the surface structure of cCpE appears to be altered more by COP-2 than COP-3, indicating that COP-specific interactions may uniquely mold cCpE’s surface due to sequence diversity (Fig. 5, B and C). We next determined if these structural features could explain the differences in binding equilibria between COP-2 and COP-3 found in vitro.

Quantification of COP binding to mutant cCpEs

To test our structures and pinpoint the amino acid determinants of COP binding, we mutated regions of cCpE where we observed potential interactions with COPs and quantified binding with BLI. Preformed claudin-4–cCpEmutant complexes were used to mimic the sFab selection experiment. First, we tested all mutants and found that no cCpEmutant affected association with claudin-4, binding with KD’s of ~270 nM, similar to WT cCpE (SI Fig. S2G) (16, 35). We then tested COP binding to claudin-4/cCpEmutant and compared to claudin-4/cCpEWT (Table 2). BLI showed that mutant cCpE1, which has a truncated N-terminus, had decreased affinity for COPs. Mutant cCpE2 increased COP affinities, this mutation lies at the end of the N-terminus at the start of globular cCpE. Mutant cCpE2 with a Leu202Ala mutation, cCpE2L, showed binding to both COPs at near cCpEWT levels but indicated a loss of affinity compared to cCpE2 due to the alanine side chain. Kinetics reveal that COPs bind claudin-4/cCpE2L at different rates compared to claudin-4/cCpE2. The mutant cCpE3 in the loop connecting β5 to β6 bound with WT affinity to COP-2 but for COP-3 had 12-fold lower affinity. Both COPs exhibited substantial losses in affinity to mutant cCpE4, which alters residue lengths in the β5 to β6 loop and β6. COP-2 affinity decreased ~270-fold while COP-3 decreased ~40-fold. Unlike the other mutants, cCpE4 affected both kinetic rates, indicating that cCpE4 perturbs normal COP binding. To put these results in a structural context, we modeled mutant cCpEs based on our cryo-EM structures with cCpEWT (SI Fig. S7). The models provide structural bases for COP binding to mutant cCpEs that explain our biophysical measurements. Overall, each set of cCpE mutants, chosen based on their potential for side chain interactions with COPs, altered COP binding in different ways, providing in vitro validation of our structures.

Model of cytotoxic claudin-bound CpE pore

To predict COP function in the context of CpE-induced cytotoxicity, we created models for the process of COP binding to the claudin-4/CpE “small complex” and for a claudin-4–bound CpE β-barrel pore complex, using the cryo-EM structures as guides. We first modeled CpE binding to claudin-4, then COP recognition of the “small complex” (Fig. 6A). The model shows in a “small complex” that CpE’s N-terminal domain would sterically shield COP access to their binding epitopes on cCpE. This finding explains our results from biophysical measurements with CpE (Table 1). We next modeled the claudin-4–bound CpE β-pore complex (Fig. 6B).
As there is no structure for the CpE β-pore, we used the cryo-EM structure of lysenin, a β-pore toxin with homology to CpE to model it (36). Lysenin was chosen because attempts to model the complex using the aerolysin β-pore, another homologous protein, did not place claudin perpendicular to the membrane plane. This model reveals that when oligomeric CpE binds to the membrane plane. This model reveals that when oligomeric CpE access to pore complexes, which reveals the cCpE-binding epitope and the CP interactions for COP-2 and COP-3 bound to claudin-4 and claudin-4/cCpE mutant complexes yield similar affinities but different kinetics, with COP-2 associating and dissociating more slowly than COP-3 (Table 1). As COPs target and bind cCpE on the opposing surface to its claudin-binding motif, they are therefore capable of binding to any claudin–cCpE complex, making them general yet strategic tools for enabling structures of claudin–cCpE complexes.

As proof of this concept, we determine cryo-EM structures for COP-2 and COP-3 bound to claudin-4–cCpE complexes, which reveal the cCpE-binding epitope and the potential interaction interfaces for the L and H chains of COPs (Fig. 2 and Fig. 3). Our structures and computational analyses show that COP-2 has an 11% larger cCpE/COP interface area, that COP-2 uses chain L CDR-L1 uniquely, and that its binding conforms to or molds cCpEs surface to a greater extent than COP-3, which explains its higher affinity and slower kinetic rates than COP-3. These analyses also reveal a common binding property to COPs where chain H interacts with both sides of a β5–β6 epitope in a mechanism similar to a caliper brake on a bicycle (Fig. 4, D and H). Holistically, the cryo-EM structures resemble and thus provide independent validation of the claudin-4–cCpE complex crystal structure.

To validate these moderate resolution cryo-EM structures, we mutate the observed COP-binding epitopes on cCpE and quantify mutatant effects to COP binding. For this, we mutated side chains in sequential three to five residue zones. We show that all mutations affect cCpE/COP binding affinity, kinetics, or both (Table 2). Some, like mutants cCpE3 and cCpE4, display COP-specific differences in their binding and thus pinpoint cCpE residues that are uniquely recognized by COP-2 or COP-3. The changes to COP binding by cCpE mutants in vitro validate our cryo-EM structures by attesting to the accuracy of their modeled cCpE/COP interfaces. We further show that models of mutant cCpE–COP complexes guided by our structures elucidate the structural bases of mutant effects to COP binding (SI Fig. S7). In sum, these results provide the likely amino acid determinants and biophysical interaction mechanisms that direct COP-specific recognition of and binding to cCpE.

### Table 2

| COP        | Claudi-4/cCpE<sub>mutant</sub> | k<sub>on</sub> (1/Ms) | k<sub>off</sub> (1/s) | K<sub>D</sub> (nM) |
|------------|---------------------------------|-----------------------|-----------------------|---------------------|
| COP-2      | cCpE<sub>WT</sub>               | 1.5x10<sup>3</sup> ± 0.1x10<sup>3</sup> | 7.8x10<sup>-4</sup> ± 0.6x10<sup>-4</sup> | 52.3 ± 3.0         |
| COP-2      | cCpE<sub>E</sub>               | 7.7x10<sup>-4</sup> ± 0.5x10<sup>3</sup> | 3.3x10<sup>-4</sup> ± 0.4x10<sup>-4</sup> | 161.3 ± 0.6        |
| COP-2      | cCpE<sub>2L</sub>              | 3.9x10<sup>-4</sup> ± 0.5x10<sup>3</sup> | 1.2x10<sup>-4</sup> ± 0.1x10<sup>-4</sup> | 8.6 ± 0.1          |
| COP-2      | cCpE<sub>E</sub>              | 1.7x10<sup>-4</sup> ± 0.1x10<sup>4</sup> | 1.0x10<sup>-3</sup> ± 0.1x10<sup>-3</sup> | 572 ± 3.7          |
| COP-2      | cCpE<sub>2L</sub>              | 1.3x10<sup>-4</sup> ± 0.1x10<sup>4</sup> | 9.4x10<sup>-4</sup> ± 0.1x10<sup>-4</sup> | 64.5 ± 4.3         |
| COP-2      | cCpE<sub>E</sub>              | 2.9x10<sup>-4</sup> ± 0.1x10<sup>4</sup> | 4.2x10<sup>-4</sup> ± 0.1x10<sup>-4</sup> | 14,200 ± 970       |
| COP-2      | cCpE<sub>4</sub>              | 2.9x10<sup>-4</sup> ± 0.7x10<sup>4</sup> | 2.7x10<sup>-3</sup> ± 0.5x10<sup>-3</sup> | 984 ± 11.0         |
| COP-3      | cCpE<sub>WT</sub>               | 1.9x10<sup>-4</sup> ± 0.2x10<sup>4</sup> | 3.9x10<sup>-5</sup> ± 0.6x10<sup>-5</sup> | 200.2 ± 5.5        |
| COP-3      | cCpE<sub>E</sub>              | 11.0x10<sup>-4</sup> ± 2.2x10<sup>4</sup> | 3.0x10<sup>-3</sup> ± 0.1x10<sup>-3</sup> | 24.6 ± 4.7         |
| COP-3      | cCpE<sub>E</sub>              | 6.3x10<sup>-4</sup> ± 0.2x10<sup>4</sup> | 5.3x10<sup>-4</sup> ± 0.1x10<sup>-4</sup> | 84.8 ± 4.8         |
| COP-3      | cCpE<sub>2L</sub>              | 3.0x10<sup>-3</sup> ± 0.3x10<sup>4</sup> | 3.9x10<sup>-5</sup> ± 1.3x10<sup>-5</sup> | 1225 ± 144         |
| COP-3      | cCpE<sub>E</sub>              | 2.7x10<sup>-4</sup> ± 0.2x10<sup>4</sup> | 9.4x10<sup>-3</sup> ± 0.1x10<sup>-3</sup> | 4010 ± 687         |

**Discussion**

Here, we demonstrate the development of sFabs called COPs, COP-2 and COP-3. We show that COPs bind well to cCpE but not to claudin-4 or CpE; COPs bind cCpE better when bound to claudin-4 than when alone in solution; and that both COPs bind the same epitope of cCpE opposite to where claudin-4 binds (Fig. 1). We also show that COP binding to claudin-4–cCpE complexes yield similar affinities but different kinetics, with COP-2 associating and dissociating more slowly than COP-3 (Table 1). As COPs target and bind cCpE on the opposing surface to its claudin-binding motif, they are therefore capable of binding to any claudin–cCpE complex, making them general yet strategic tools for enabling structures of claudin–cCpE complexes.
We further present models for the claudin-4/CpE “small complex” and claudin-4–bound CpE β-pore complex in order to understand our structures in a functional context and to predict COP efficacy for use as CPOs (Fig. 6). One model shows that when CpE is bound to claudin-4 in a “small complex”, the N-terminus of CpE sterically shields COP-binding epitopes (Fig. 6A). This model is verified by our finding that COP-2 and COP-3 bound CpE with ~100-fold lower affinity than cCpE (Table 1). Using the homologous β-pore–forming toxin lysenin as a benchmark, we also show how CpE may oligomerize to form its membrane-spanning β-pore upon binding to claudin-4 (Fig. 6B). This model shows that COPs are sterically occluded from accessing their epitopes on cCpE due to CpE oligomeric assembly and N-terminal β-pore engagement (Fig. 6C). Based on this model, we hypothesized that COPs would be ineffective at preventing CpE-induced...
cytotoxicity. We test this hypothesis using a cell-based cytotoxicity assay and show that COPs do not prevent nor alter cytotoxicity induced by CpE (Fig. 6C). This finding verifies our hypothesis and provides evidence that our model of the CpE β-pore is potentially useful to predict the functional effects of structural changes to CpE upon binding claudin-4 and forming a cytotoxic β-pore.

Based on these data and results, we propose a framework for using COP-like molecules to target and obstruct CpE cytotoxicity (Fig. 7). We envision three strategies based on the proposed sequence of events that lead to CpE β-pore formation (17, 18). These include developing COPs that 1) obstruct formation of claudin-4/CpE “small complexes”, 2) stabilize the native fold of CpE’s N-terminus to prevent its structural rearrangement that induces cytotoxicity via β-pore formation, and 3) obstruct CpE oligomerization prior to β-pore assembly. Using our models for the “small” and claudin-4-bound CpE β-pore complexes, we identify five areas where binding by COP-like sFabs could obstruct CpE binding, conformational changes, or oligomerization, potentially preventing CpE-based cytotoxicity. Area A is a surface pocket between β8 and β9 on the cCpE domain of CpE (Fig. 7A); and area B comprises the two ECS of claudins and includes the NPLVA153 motif that imparts high-affinity CpE binding (Fig. 7B) (16). Development of COPs that bind area A or B would inhibit formation of the “small complex” by obstructing areas known to facilitate claudin-4–cCpE interactions, thus preventing CpE prepore and β-pore complex formation (Strategy 1). Area C is a region of CpE’s N-terminus that may structurally rearrange upon CpE assembly forming a long, antiparallel β-barrel to create the membrane-penetrating β-pore (Fig. 6B and Fig. 7C). Discovery of COPs that bind area C may stabilize CpE’s N-terminus to disable its β-pore–forming conformational transition (Strategy 2)—they may also obstruct CpE oligomerization (Strategy 3). Finally, area D includes strand β1 and helix α1 of cCpE; while area E comprises two loops that connect β2 to β3 and β8 to β9 (Fig. 7C). Based on our models, areas D and E represent additional areas where COP binding could sterically obstruct CpE oligomerization. In summary, our models reveal that 1) for COP binding to areas A or B to be effective at obstructing cytotoxicity, they will need to be present before or during CpE production to prevent “small complex” formation and 2) COP binding to areas C, D, or E would not prevent “small complex” formation and thus could be effective postproduction of CpE but would need to be present prior to CpE’s oligomeric assembly of its β-pore. This proposed structure-based framework can inform therapeutic strategies that utilize yet to be developed COPs to target CpE, claudin-4, or claudin-4–CpE complexes. COPs that bind the above-mentioned areas could obstruct CpE β-pore formation and thus prevent CpE-linked cytotoxicity. Such molecules could be potent therapeutics, capable of treating CpE-linked gastrointestinal illnesses, afflict millions of humans and domesticated animals globally, resulting in large economic burdens and losses in quality of life.

Conclusions

In this study, we progress a novel workflow for structural determination of claudin–enterotoxin complexes using 200 kV cryo-EM instrumentation that yields 4 to 7 Å resolutions. Our approach is amenable to other cCpE-binding claudins in a variety of membrane mimetics and is enabled by COPs, which add mass, rigidity, and act as fiducial marks (SI Fig. S8). COPs are versatile, capable of being used for cryo-EM and/or as crystallization chaperones for X-ray diffraction. Although the cryo-EM workflow described here produces modest resolution structures, it must be considered that these complexes are small by cryo-EM standards at 35 kDa. We estimate that their already detailed maps could be improved to 3 to 4 Å using

Figure 7. COP targeting strategies to obstruct CpE cytotoxicity. A, COPs (blue) that target the cCpE domain of CpE (copper) by binding to Area A, a solvent-accessible pocket between β8 and β9 of cCpE that is known to interact with claudin-4’s NPLVA153 motif, which is critical for “small complex” formation. B, COPs (blue) that target hCLDN-4 (teal) by binding to Area B, the two ECS of claudins, which coordinate to interact with cCpE and form a “small complex”. C, COPs (red, black, green) that target CpE (copper) by binding to Areas C, D, and E. Area D comprises Pro65-Pro124 of CpE’s N-terminus, which contains a purported Thr92-Gly105 α-helix used for β-pore formation. Area D comprises Ala203-Asn218 of cCpE, which contains its β1 strand and α1 helix. Area E comprises Ser229-Asn236 and Ser304-Pro311 of cCpE, which contain two loops that connect strands β2 to β3 and β8 to β9. These three areas may be used for CpE assembly and thus COP binding could obstruct this assembly, trapping “small complexes” that are inert and not cytotoxic. cCpE, CpE’s C-terminal domain; COP, CpE obstructing protein; ECS, extracellular segment.
Cryo-EM structures of claudin–enterotoxin complexes by Fabs

300 kV microscopes (SI Fig. S4). Achieving these resolutions would equal current results from crystallography of claudin–cCpE complexes and have the added advantage of enabling structure determination of complexes recalcitrant to crystallization or complexes that crystallize but diffract X-rays weakly. Thus, COPs are multiuse tools to expand structural knowledge of other claudins that bind enterotoxins. For this and their potential obstructing capacities, COPs and COP-like sFabs may provide new insights useful for developing treatments for CpE-based diseases or to aid design of novel cCpE and CpE-based therapeutics that modulate tight junction barriers.

Experimental procedures

Claudin-4 and enterotoxin expression and purification

Methods followed those described previously (16, 24). Briefly, claudin-4, cCpE, and CpE with C-terminal decahistidine tags preceded by thrombin cleavage sites (claudin-4-His10, cCpE-His10, and CpE-His10) were cloned into pFastBac1 (ThermoFisher) and expressed in Trichoplusia ni (High Five, Expression Systems, LLC). Cell pellets resuspended in lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1 mM PMSF, and EDTA-free SigmaFast protease tablets (Sigma)) were sonicated, supplemented with 1 M NaCl, then ultracentrifugation at 100,000×g for 1 h. For enterotoxins, the supernatant was saved, 15 mM imidazole was added along with NiNTA resin, and the solution was incubated for 12 h at 4 °C. For claudin-4, the supernatant was removed, and the membrane pellet was resuspended in lysis buffer and the protein was solubilized with 1% (w/v) DDM (Anatrace) and 0.04% cholesteryl hemisuccinate (Anatrace) overnight at 4 °C. Insoluble protein was removed by ultracentrifugation at 100,000×g for 30 min, and the supernatant was treated with 15 mM imidazole along with NiNTA resin, and the solution was incubated for 12 h at 4 °C. For claudin-4, the bound protein was captured and washed with five column volumes of buffer A (50 mM Tris pH 7.4, 500 mM NaCl, 25 mM imidazole, and 0.087% DDM) and buffer B (buffer A containing 300 mM NaCl and 40 mM imidazole). Buffer T (50 mM Tris pH 8.0, 150 mM NaCl and 0.04% DDM) was used to release and capture proteins from the resin after treatment with thrombin. For enterotoxins, purification was similar to claudin-4 except DDM was not added to buffers. These proteins were then used for sFab panning or biochemical, biophysical, and structural analyses. For enterotoxins used for binding studies, the proteins were eluted off of NiNTA using elution buffer (buffer T containing 400 mM imidazole) to keep the His10 tag. Eluted enterotoxin-His10 was dialyzed in SEC buffer (10 mM Hepes pH 7.4, 100 mM NaCl, and 4% glycerol), concentrated to 1 mg/mL, then flash-frozen in liquid nitrogen and stored at −80 °C until use.

Generation and validation of COPs using phage display

DDM-solubilized claudin-4 was biotinylated using N-hydroxysuccinimide polyethylene glycol biotin (NHS-PEG4-biotin, ThermoFisher) by mixing 5.6 μM claudin-4 with 16.8 μM NHS-PEG4-biotin, followed by incubation on ice for 2 h. Excess cCpE with the His10 removed was added at a ratio of 1:1.5 (mole:mole), then free biotin and unbound cCpE was removed by loading the sample onto a Superdex 200 Increase 10/300 GL (Cytiva) equilibrated in SEC buffer containing 0.04% DDM. The sFab panning was performed using the sFab library E (32, 33). Binding was assayed in selection buffer (25 mM Hepes pH 7.4, 150 mM NaCl, and 1% bovine serum albumin). A first round of panning was performed manually using 200 nM of biotinylated claudin-4/cCpE in DDM immobilized onto magnetic beads, and following three washes with Selection buffer, the beads enriched for phage-expressing claudin-4/cCpE-specific sFabs were used to infect log-phase Escherichia coli XL1-Blue cells. Phages were amplified overnight in 2xYT media supplemented with 100 μg/ml ampicillin and M13-KO7 helper phage (109 pfu/ml). Selection stringency was then increased by four additional rounds of panning using decreasing claudin-4/cCpE concentrations down to ~20 nM. For each round, the amplified phage pool from each preceding round was used as the input. For rounds two to five, panning was performed semiautomatically using a Kingfisher magnetic beads handler (ThermoFisher). Nonspecific binding of sFabs to detergent was reduced by using >0.87% DDM in later rounds. Bound phage particles were removed by elution from beads using 1% Fos-choline-12.

The initial validation was performed by single-point phage ELISA using individual clones from later selection rounds. ELISAs were performed in 96-well plates (Nunc) coated with 2 μg/ml neutravidin and blocked with selection buffer. E. coli XL1-Blue colonies–containing phagemids were used to inoculate 400 μl 2xYT media containing 100 μg/ml ampicillin and 109 pfu/ml M13-KO7 helper phage. Phages were amplified overnight in 96-well deep well blocks at 37 °C with shaking at 280 rpm. Phages were then diluted 1:10 into selection buffer and assayed against claudin-4/cCpE in DDM or buffer containing only DDM micelles. Biotinylated claudin-4/cCpE was immobilized at room temperature for 30 min, then incubated with phage dilutions. Bound phage were detected with TMB substrate (ThermoFisher) following a 30 min incubation with horseradish peroxidase–conjugated anti-M13 monoclonal antibody (GE Healthcare). Absorbance was measured at 450 nm after quenching the reaction with 1.0 M HCl. Wells containing 1% DDM were used to detect nonspecific binding.

COP expression and purification

Two sFabs termed COP-2 and -3, from phage ELISA, were selected and sequenced at the University of Chicago Comprehensive Cancer Center DNA Sequencing facility. Unique clones for each COP were subcloned in pRH2.2 using the In-Fusion Cloning kit (Takara Bio). Sequence-verified COPs were transformed into E. coli BL21-Gold cells (Agilent) and then used to inoculate overnight cultures. The inoculates were then used to seed 1 l of 2xYT media containing 100 μg/ml ampicillin. Cultures were grown to an A600 of 0.8, induced for 4 h at 37 °C, then cells were harvested using
centrifugation. Cell pellets were resuspended in COP lysis buffer (20 mM Hepes pH 7.4, 150 mM NaCl, 0.5 mM MgCl₂, 1 mM PMSF, and 1 µg/ml DNase I). Cells were sonicated and lysates were incubated at 60 °C for 30 min to remove proteolyzed fragments. Samples were cooled rapidly on ice then cleared by centrifugation. Supernatants were filtered by 0.45 µm and loaded onto a 5 ml HiTrap MabSelect SuRe column (GE Healthcare) equilibrated with COP Wash buffer (20 mM Hepes pH 7.4 and 500 mM NaCl). The column was washed with 10 column volumes of COP Wash buffer, and COPs were eluted with 0.1 M acetic acid. Eluted COPs were washed with 10 column volumes of this buffer. The COPs were then eluted by 0.25 M NaCl and loaded onto a 5 ml HiTrap MabSelect SuRe column (GE Healthcare) equilibrated with COP Wash buffer (20 mM Hepes pH 7.4 and 500 mM NaCl). The column was washed with 10 column volumes of COP Wash buffer, and COPs were eluted with 0.1 M acetic acid. Eluted COPs were loaded onto a 1 ml Resource S column (GE Healthcare) equilibrated with COP buffer A (50 mM sodium acetate pH 5.0) and washed with 10 column volumes of this buffer. The COPs were eluted by linear 0 to 50% gradient with COP buffer B (COP buffer A containing 2 M NaCl). COP-containing fractions were pooled and dialyzed overnight at 4 °C in SEC buffer.

**Biochemical characterization of COP binding**

We used post-NiNTA–purified untagged claudin-4 and enterotoxins and postaffinity-purified COPs for these analyses. For claudin-4/COP and enterotoxin/COP studies, 50 µg enterotoxins was used and excess COPs were added at a 1:1.2 M ratio, incubated at room temperature for 1 h, concentrated, 0.2 µm filtered, then loaded onto a Superdex 200 column equilibrated in SEC buffer containing 0.04% DDM. For claudin-4/enterotoxin/COP studies, 50 µg claudin-4 was used and excess enterotoxins were added at a 1:1.2 M ratio, then COPs were added at a 1:1 M ratio to enterotoxins. Complexes were incubated, concentrated and filtered, and loaded onto a Superdex200 column equilibrated in SEC buffer and 0.04% DDM. Complex formation was assessed by observed decreases in the elution times of the uncomplexed peak fractions. Peak fractions containing complexes were pooled, unboiled, and evaluated for the presence of each protein by SDS-PAGE using 4 to 20% agarose gradient gels.

**Biophysical characterization of COP binding using BLI**

BLI analyses were performed at 25 °C at an acquisition rate of 5 Hz averaged by 20 using an Octet® BLItz System (FortéBio/Sartorius), with assays designed and setup using Blitz Pro 1.3 Software. A typical experiment consisted of the following steps: sensor equilibration (30 s), protein loading (200 s), baseline (60 s), and association and dissociation (300 s each). For the loading step, 4 µl of proteins were loaded in the drop holder, while all other steps were performed in transparent 600 µl microtubes using 250 µl sample volumes. All measurements were performed in SEC buffer containing 0.04% DDM. For cCpE/COP studies, 5 µM (70 µg/ml) of WT cCpE-His₁₀ was loaded on NiNTA (Dip and Read) sensors then dipped into a 0 to 1 µM range of four concentrations of COPs for the association steps. For claudin-4/enterotoxin/COP studies, 5 µM DDM-solubilized claudin-4 biotinylated with NHS-PEG4-biotin as before was precomplexed with excess WT or mutant cCpE or CpE without a His₁₀ at a ratio of 1:2 (moles:moles) for 1 h at room temperature. Claudin-4–enterotoxin complexes were loaded on Streptavidin-SA (Dip and Read) sensors and the measurements were performed as above using 0 to 30 µM range of concentrations depending on the analyte. For claudin-4/mutant cCpE studies, 5 µM of biotinylated claudin-4 in DDM was immobilized on SA sensors and measurements were performed as above using 0 to 0.25 µM concentration range of cCpEs. For all studies, measurements were repeated in at least duplicate, and the time courses for association and dissociation were fit to one-site–binding model using the BLItz Pro 1.3 Software. No major nonspecific binding of COPs to unloaded NiNTA or streptavidin sensors were detected at concentrations up to 30 µM.

**Cryo-EM sample preparation**

DDM-solubilized claudin-4 was exchanged into 2,2-didecylpropane-1,3-bis-β-D-maltopyranoside (LMNG, Ana- trace) or amphipil A8-35 (Anatrace). For exchange into LMNG, the protein bound to NiNTA resin was sequentially washed with buffer A, B, and T containing 0.087, 0.087, and 0.04% LMNG, respectively, before releasing the bound protein from resin via thrombin cleavage. To prepare sample in amphipil, 1 mg of postthrombin-digested claudin-4 in DDM was treated with 4 mg of amphipil (1:4 w/w) for 2 h before removing detergent via addition of 400 mg SM-2 biobeads (Bio-Rad). Excess cCpE was added to each claudin-4 sample at a molar ratio of 1:1.5, incubated at room temperature for 1 h, then excess COPs were added at a 1.5:1 ratio to cCpE. After 1 h at room temperature, each sample was concentrated, 0.2 µm filtered, and then loaded onto a Superdex 200 Increase 10/300 Gl equilibrated in SEC buffer without glycerol but with 0.003% LMNG or no detergent for amphipil samples. Peak fractions from SEC-containing claudin-4–cCpE–COP complexes were collected and concentrated to 6 to 8 mg/ml for use in cryo-EM analyses.

Grids for cryo-EM analyses were prepared using a Vitrobot Mark IV (ThermoFisher) plunge freezing apparatus. Aliquots (3 µl) of claudin-4–cCpE–COP complexes in LMNG or amphipil were applied to Quantifoil R1.2/1.3200 mesh grids that were glow-discharged for 45 s at 15 mA in a Pelco easi-Glow (Ted Pella Inc) instrument. Protein solutions were applied to grids at 4 °C and 100% relative humidity and allowed to adsorb on the grid for ~30 s before blotting. Grids were blotted for 5 to 8 s with a blot force of 1 and plunged frozen into liquid ethane cooled by liquid nitrogen. Grids were stored in liquid nitrogen prior to imaging.

**Cryo-EM data collection and processing**

Cryo-EM data collection was performed on a Talos Arctica (ThermoFisher) equipped with a Falcon III (ThermoFisher) direct electron detector at Michigan State University. Grids were screened for thin ice and good particle distribution, and data collection was performed using EPU software (ThermoFisher). Movies of claudin-4–cCpE/COP-2 in LMNG were collected on the Falcon III detector in counting mode at 92000× magnification with a pixel size of 1.12 Å, a defocus...
Cryo-EM structures of claudin–enterotoxin complexes by Fabs

range of 0.8 to 2.6 μm, and a total dose of ~32 electron/Å² fractionated over 51 total frames. Movies of claudin-4/cCpE/COP-3 in amphiphil were collected at 120000x magnification with a pixel size of 0.87 Å, a defocus range of ~1 to ~2.2 μm, and a total dose of ~40 electron/Å² fractionated over 42 total frames.

All micrograph and particle processing was performed in CryoSPARC (39). Patch-motion correction and patch-CTF correction were used to correct for beam-induced motion and calculate CTF parameters from the motion-corrected micrographs. Blob-based template picking followed by 2D classification was used to generate templates that were subsequently used for template-based particle picking. Particles identified from this template-based picking procedure were subjected to several rounds of 2D classification, followed by ab initio 3D reconstruction, heterogeneous refinement, and nonuniform refinement. In the case of the COP-3 complex, local refinement using a soft mask around cCpE and COP-3 was also used to improve resolution at the complex’s interface.

Cryo-EM model building, refinement, and structure determination

Using postprocessing maps, we first built the structure of claudin-4/cCpE/COP-2 using the 6.9 Å map and the crystal structure of claudin-4 in complex with cCpE (PDB ID 7KP4) (16). 7KP4 was manually docked by placing the four TMs of claudin-4 into density present in the LMNG micelle using Coot (40). TM placement was validated using density corresponding to bulky side chains, like Trp18 in TM1 of claudin-4. Initial placement of the TM region showed that only minor alterations to claudin-4’s ECS and cCpE would be required to fit well within the cryo-EM map. For this part of the structure, the map volume allowed placement of most claudin-4 and cCpE residues, with the exception of claudin-4’s C-terminus and cCpE’s N-terminus. We next built COP-2 by first using a high-resolution crystal structure of an sFab (PDB ID 6CBV). COP-2 was manually docked into the additional cryo-EM density using Coot, and then divergent residues of COP-2 were manually mutated from the 6CBV template using sequence alignments as a guide (41). Once the three proteins were fit manually, each of the four protein chains were rigid body refined in Coot to place the structure within the cryo-EM map volume. Model building was done using Coot and once complete, the structure was further refined using a combination of molecular dynamics (MD) flexible fitting simulations using Namdinator followed by real-space refinement of the model into the cryo-EM density map using Phenix phenix.real_space_refine using secondary structure and Ramachandran restraints (42, 43). The final structural model required secondary structure and Ramachandran restraints to optimize the model-to-map fit and overall geometry. SI Table S1 shows data collection, refinement, and validation statistics for the claudin-4/cCpE/COP-2 structure.

The structure of claudin-4/cCpE/COP-3 was determined using both a masked and unmasked strategy, which produced focused and whole maps that resolved to 3.8 and 5.0 Å, respectively. A mask was applied to COP-3 and cCpE of the complex in the former case, while all three proteins were included (unmasked) in the latter. The final model of the claudin-4–cCpE–COP-2 complex was manually docked, then COP-3 was made from COP-2 by mutating divergent residues using sequence alignments. Each protein chain in the complex was then individually refined as rigid bodies into the cryo-EM maps using Coot. While the focused map had added features for COP-3 and cCpE, because of the mask, it lacked density for claudin-4 and refinements using the three-protein complex resulted in poor model-to-map fits. Thus, all three proteins were built and fit manually within the whole map volume using Coot and the final model was refined using Namdinator and Phenix phenix.real_space_refine using secondary structure and Ramachandran restraints (42, 43). The deposited PDB ID 7TDN is a result of refining against the whole cryo-EM map. SI Table S1 shows data collection, refinement, and validation statistics for the claudin-4/cCpE/COP-3 structure.

The programs used to visualize and build the structures included Coot, PyMOL, and Chimera, refined using Phenix, and Figures were made using PyMOL—using the SBGrid Consortium Software Suite (40, 44–47).

Mutagenesis of cCpE

The cCpE-His10 was altered using site-directed mutagenesis. Mutants were generated with the following forward and equivalent reverse primers:

cCpE1

5’-gctcgggatccgccccagggattaggttaagaaaacatcgac-3’
cCpE2

5’-ccatgtcaacgggacattgtaagaaaaacagccgctgtcaggtcgacagacgc-3’
cCpE3

5’-cggtttacatttaaccctttccacgccccgcctgtcctggtttcaaactct-accgggagaatgtc-3’
cCpE4

5’-cattctcattaactcttaaatagctgcaactgaccgcaacatgccgagatgg-3’. Expression and purification of all cCpE-His10 mutants were identical to those of WT cCpE-His10. Amino acid sequence alignments comparing mutant cCpE to WT are provided to aid interpretation.

Structural modeling of claudin-bound CpE pore

A model of claudin-4/CpE was made by superposing CpE (PDB ID 3 AM2) onto cCpE from our cryo-EM structure of the COP-2 complex, making a claudin-4/CpE/COP model. To approximate the CpE β-pore, we modeled it after lysenin, a β-pore toxin with homology to CpE, using an available cryo-EM structure present in the 6CBV micelle.
structure (PDB ID 5GAQ) (36, 48). Using a crystal structure of the lysenin monomer (PDB ID 3ZXD), we superposed 3ZXD onto one monomer of the 5GAQ nonamer and then superposed the CpE portion of our claudin-4/CpE/COP model onto 3ZXD (49). We next removed 3ZXD. This process integrated claudin-4/CpE/COP into lysenin, making the model for the claudin-4–bound CpE β-pore. These models were used to predict COP influence on CpE-induced cytotoxicity.

Cell-based cytotoxicity assay

Recombinant baculoviruses—containing claudin-4–His10 were produced using established methods and the cytotoxicity assay was performed using methods previously described (16). To 18 wells of a 24-well cell culture plate, 0.5 ml of 1.0 × 10⁶ adherent Sf9 (S. frugiperda, Expression Systems) cells were added. After 1 h at 27 °C, virus–containing claudin-4–His10 was added at a MOI of 1.0. Cultures were rocked gently and then placed at 27 °C for 48 h. The 18 wells were divided into three, 6-well groups. To duplicate wells of group one and three, 22 µg (0.9 µM) of COP-2 was added; to a second pair of wells, 22 µg (0.9 µM) of COP-3 was added; and to the third pair of wells, no COP was added. To duplicate wells of group two, 100 µg (4 µM) of COP-2 was added; to a second pair of wells, 100 µg (4 µM) of COP-3 was added; and to the third pair of wells, no COP was added. For group one, nothing more was added; this group contained only cells expressing claudin-4–His10. For group two, 25 µg (3.3 µM)–purified cCpE in SEC buffer was added to the culture medium. For group three, 12.5 µg (0.7 µM) CpE in SEC buffer was added to the culture medium. The COP amounts added correspond to 1.2-fold molar excess of COP to enterotoxin. After addition of COPs and/or enterotoxins, Sf9 cells were placed at 27 °C for 12 h, then CpE cytotoxicity was quantified using a cell viability assay. This was done by gently removing 250 µl of Sf9 cells from each well, centrifuging at 200 × g for 2 min, removing 200 µl of media, then adding 50 µl of 0.04% trypan blue. After 5 min, 10 µl of stained cells were transferred to a Countess cell counting chamber slides and counted automatically using a Countess 3 automated cell counter (ThermoFisher). Each well was counted at least two times with one well counted three times (representing five readings per sample, 45 for nine samples). Viability counts consisted of dividing the total number of live cells (unstained) by the total number of cells. Average cell viability for enterotoxin-treated cells was compared to Sf9 cells expressing claudin-4 that were not treated with either enterotoxins or COPs. Data was plotted as a mean with SD in GraphPad Prism 9 for macOS.

Data availability

The cryo-EM structure of claudin-4/cCpE/COP-2 has accession code 7TDN in the Protein Data Bank (PDB), and cryo-EM maps of this complex have been deposited to the Electron Microscopy Data Bank under accession code EMD-25834. The cryo-EM structure of claudin-4/cCpE/COP-3 has PDB accession code 7TDN, and cryo-EM maps of this complex have been deposited to the Electron Microscopy Data Bank under accession code EMD-25835 (whole) and EMD-25836 (focused).

Supporting information—This article contains Supporting information (50).

Acknowledgments—We are grateful to the RTSF Cryo-EM Microscopy Facility at Michigan State University and Dr Sundharraman Subramanian for providing time and support for cryo-EM data collection.

Author contributions—B. J. O., P. K. D., S. R., C. P. O., S. K. E., and A. J. V. investigation; B. J. O. and A. J. V. formal analysis; B. J. O., P. K. D., and A. J. V. validation; B. J. O., A. A. K., and A. J. V. writing—review and editing; P. K. D., A. A. K., and A. J. V. methodology; A. A. K. and A. J. V. conceptualization; A. A. K. and A. J. V. resources; A. A. K. and A. J. V. funding acquisition; A. J. V. data curation; A. J. V. writing—original draft; A. J. V. visualization; A. J. V. supervision; A. J. V. project administration.

Funding and additional information—Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM138368 (to A. J. V.) and R01GM117372 (to A. A. K). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: BLI, bio-layer interferometry; cCpE, CpE’s C-terminal domain; COP, CpE obstructing protein; CpE, Clostridium perfringens enterotoxin; DDM, n-dodecyl-β-D-maltopyranoside; ECS, extracellular segment; NHS-PEG4-biotin, N-hydroxysuccinimide polyethylene glycoc biotin; SEC, size-exclusion chromatography; sFab, synthetic antigen-binding fragment; TM, transmembrane.

References

1. Chiba, H., Osanai, M., Murata, M., Kojima, T., and Sawada, N. (2008) Transmembrane proteins of tight junctions. Biochim. Biophys. Acta 1778, 588–600
2. Anderson, J. M., and Van Itallie, C. M. (2009) Physiology and function of the tight junction. Cold Spring Harb Perspect. Biol. 1, a002584
3. Anand, R., Fujita, K., Hiraiga, T., Fujimoto, K., and Tsukita, S. (1998) Claudin-1 and -2: Novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J. Cell Biol. 141, 1539–1550
4. Katoh, H., Sugiyama, H., Inoue, N., Sugimoto, K., and Sugimoto, N. (1997) Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J. Biol. Chem. 272, 26652–26658
5. McClane, B. A. (2001) The complex interactions between clostridium perfringens enterotoxin and epithelial tight junctions. Toxicon 39, 1781–1791
6. Rood, J. I., Adams, V., Lacey, J., Iyars, D., McClane, B. A., Melville, S. B., et al. (2018) Expansion of the clostridium perfringens toxin-based typing scheme. Anaerobe 53, 5-10
Cryo-EM structures of claudin-enterotoxin complexes by Fabs

7. Uzal, F. A., Freedman, J. C., Shrestha, A., Theoret, J. R., Garcia, J., Awad, M. M., et al. (2014) Towards an understanding of the role of claudin perfringens toxins in human and animal disease. *Future Microbiol.* 9, 361–377
8. Freedman, J. C., Shrestha, A., and McClane, B. A. (2016) Clostridium perfringens enterotoxin: action, genetics, and translational applications. *Toxins (Basel)* 8, 73
9. Scallen, E., Hoekstra, R. M., Angulo, F. J., Tauxe, R. V., Widdowson, M. A., Roy, S. L., et al. (2011) Foodborne illness acquired in the United States—major pathogens. *Emerg. Infect Dis.* 17, 7–15
10. Hoffmann, S., Batz, M. B., and Morris, J. G., Jr. (2012) Annual cost of illness and quality-adjusted life years lost in the United States due to foodborne pathogens. *J. Food Prot.* 75, 1292–1302
11. Scharf, R. L. (2012) Economic burden from health losses due to foodborne illness in the United States. *J. Food Prot.* 75, 123–131
12. Kirk, M. D., Pires, S. M., Black, R. E., Caipo, M., Crump, J. A., Devlees, et al. (2012) Economic burden from health losses due to foodborne illness due to 14 foodborne pathogens. *J. Food Prot.* 75, 1292–1302
13. Vecchio, A. J., and Stroud, R. M. (2019) Claudin-9 structures reveal mechanism for toxin-induced gut barrier breakdown. *Proc. Natl. Acad. Sci. U S A.* 106, 2755–2760
14. Mitchell, L. A., and Koval, M. (2010) Specificity of interaction between claudin perfringens enterotoxin and claudin-family tight junction proteins. *Toxins (Basel)* 2, 1336–1356
15. Wu, S., Avila-Sakar, A., Kim, J., Booth, D. S., Greenberg, C. H., Rossi, A., et al. (2012) Clostridium perfringens enterotoxin complexes by Fab module for single particle cryo-EM studies of small proteins. *Structure* 20, 582–592
16. Bukowska, M. A., and Grutter, M. G. (2013) New concepts and aids to facilitate crystallization. *Curr. Opin. Struct. Biol.* 23, 409–416
17. Tachibana, K., Iwashita, Y., Wakayama, E., Nishino, I., Nishikaji, T., and Murayama, S. (2010) Structural insight into tight junction disassembly by Clostridium perfringens enterotoxin. *Front. Immunol.* 9, 2320
18. Tachibana, K., Iwashita, Y., Wakayama, E., Nishino, I., Nishikaji, T., and Murayama, S. (2010) Structural insight into tight junction disassembly by Clostridium perfringens enterotoxin. *Front. Immunol.* 9, 2320
19. Mitchell, L. A., and Koval, M. (2010) Specificity of interaction between claudin perfringens enterotoxin and claudin-family tight junction proteins. *Toxins (Basel)* 2, 1595–1611
20. Maeda, T., Murata, M., Chiba, H., Takasawa, A., Tanaka, S., Kojima, T., et al. (2012) Claudin-4-targeted therapy using clostridium perfringens enterotoxin for prostate cancer. *Prostate* 72, 351–360
21. Saitoh, Y., Suzuki, H., Tani, K., Nishikawa, K., Irie, K., Ogura, Y., et al. (2015) Structural insight into tight junction disassembly by claudium perfringens enterotoxin. *Structure* 23, 775–778
22. Shinoda, T., Shinya, N., Ito, K., Ishizuka-Katsura, Y., Ohnawa, N., Terada, T., et al. (2016) Cell-free methods to produce structurally intact mammalian membrane proteins. *Sci. Rep.* 6, 30442
23. Mitic, L. L., Unger, V. M., and Anderson, J. M. (2003) Expression, solubilization, and biochemical characterization of the tight junction transmembrane protein claudin-4. *Proteins Sci.* 12, 218–227
24. Suzuki, H., Nishikawa, T., Tani, K., Yamazaki, Y., Tamura, A., Ishitani, R., et al. (2014) Crystal structure of a claudin provides insight into the architecture of tight junctions. *Science* 344, 304–307
25. Punjani, A., Rubinstein, J. L., Fleet, D. J., and Brubaker, M. A. (2017) cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat. Methods* 14, 290–296
26. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* 66, 486–501
27. Mukherjee, S., Erramilli, S. K., Ammirati, M., Alvarez, F. J. D., Fennell, K. F., Purdy, M. D., et al. (2020) Synthetic antibodies against BRIL as universal fiducial marks for single-particle cryo-EM structure determination of membrane proteins. *Nat. Commun.* 11, 1596
28. Afonine, P. V., Poon, B. K., Read, R. J., Sobolev, O. V., T., and Berg, P. P. (2019) Namdinator - automatic molecular dynamics flexible fitting of structural models into cryo-EM and cryoEM crystallography experimental maps. *IUCrJ* 6, 526–531
29. Schrödinger, L. and Delano, W. (2022) PyMOL. Version 2.2.3. Schrödinger, LLC, New York, NY
30. Petters, E. F., Goddard, T. D., Huang, C. C., Couch, K. G., Greenblatt, D. M., Meng, E. C., et al. (2004) UCSF Chimera—a visualization system for exploratory research and analysis. *J. Comput. Chem.* 25, 1605–1612
31. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., et al. (2010) Phenix: A comprehensive python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.* 66, 213–221
32. Morin, A., Eisenbraun, B., Key, J., Sanschafrin, P. C., Timony, M. A., Ottaviano, M., et al. (2013) Collaboration gets the most out of software. *Elife* 2, e01466.
Cryo-EM structures of claudin–enterotoxin complexes by Fabs

48. Bokori-Brown, M., Martin, T. G., Naylor, C. E., Basak, A. K., Titball, R. W., and Savva, C. G. (2016) Cryo-EM structure of lysenin pore elucidates membrane insertion by an aerolysin family protein. Nat. Commun. 7, 11293

49. De Colibus, L., Sonnen, A. F., Morris, K. J., Siebert, C. A., Abrusci, P., Plitzko, J., et al. (2012) Structures of lysenin reveal a shared evolutionary origin for pore-forming proteins and its mode of sphingomyelin recognition. Structure 20, 1498–1507

50. Notredame, C., Higgins, D. G., and Heringa, J. (2000) T-coffee: a novel method for fast and accurate multiple sequence alignment. J. Mol. Biol. 302, 205–217